Soft-Tissue versus Hematologic Primary Malignant Cardiac Tumors: Demographics and First-Course Treatment Patterns in the SEER Registry

The human heart is a relentless engine, beating roughly 100,000 times a day to keep blood moving through the body. While it is a powerful muscle, it is also a place where rare and dangerous growths can sometimes take root. Most tumors that appear in the heart are actually benign, meaning they are not cancerous and do not spread. However, a small fraction of these growths are malignant, or cancerous, and they pose a severe threat to life. These rare cancers are not all the same; they are a collection of different diseases that happen to share the same location. Some arise from the connective tissues that support the heart, while others originate from the blood system itself. Because these tumors are so uncommon, doctors have historically struggled to understand them as a single group, often treating them with a one-size-fits-all approach that may not fit the specific biology of the patient.

A team of researchers recently turned to a massive national database to untangle this complexity. By looking at thousands of recorded cases over two decades, they sought to see if separating these tumors by their biological origin—specifically, whether they came from soft tissue or the blood system—revealed distinct patterns in who gets sick, how the disease behaves, and what treatments are used. Their work does not offer a new cure or a guaranteed survival plan, but it provides a clearer map of the landscape. It shows that these two groups of heart cancers are fundamentally different in their nature, affecting different types of people and responding to different medical strategies. Understanding these differences is the first step toward moving away from a generic approach and toward care that is tailored to the specific biology of the tumor.

The researchers analyzed data from the Surveillance, Epidemiology, and End Results program, a comprehensive registry that tracks cancer cases across the United States. They focused on 730 patients diagnosed with primary malignant cardiac tumors between the years 2000 and 2021. After carefully sorting these cases, they divided them into two main categories: soft-tissue tumors and hematologic tumors. Soft-tissue tumors are cancers that grow from the structural materials of the heart, such as muscle or connective tissue. Hematologic tumors are cancers that arise from the blood or immune system cells within the heart. The study excluded a small number of cases that did not fit neatly into these groups or lacked necessary data, leaving a clear picture of the two dominant types.

One of the most striking findings was that these two types of cancer do not strike the same people. The soft-tissue tumors were most common in middle-aged adults, with the majority of patients falling between 45 and 64 years old. In contrast, the hematologic tumors were overwhelmingly a disease of the elderly, with nearly two-thirds of those patients being 65 or older. There was also a difference in gender; while soft-tissue tumors affected men and women in nearly equal numbers, the hematologic tumors were more likely to occur in men. This suggests that the biological drivers of these cancers are distinct, affecting different populations at different stages of life.

The study also provided a detailed inventory of exactly what these tumors were made of. Among the soft-tissue group, the most common specific type was a cancer called angiosarcoma, which accounts for nearly half of all soft-tissue cases. This is a fast-growing cancer that starts in the lining of blood vessels. The hematologic group was dominated by a specific type of blood cancer known as diffuse large B-cell lymphoma, which made up more than 60 percent of those cases. By identifying these specific names, the researchers moved beyond vague categories and highlighted that the heart is being attacked by very specific, well-known diseases that happen to be located there.

When the researchers looked at how doctors treated these patients, the differences between the two groups became even more apparent. For the soft-tissue tumors, the most common first step was surgery. About two-thirds of patients with these tumors underwent a procedure to remove the cancer from the heart. This aligns with the idea that if a solid mass can be cut out, it is often the best first option. Conversely, for the hematologic tumors, surgery was rarely the first choice, with only about one in six patients undergoing an operation. Instead, the standard approach for these blood-based cancers was chemotherapy, a treatment that uses drugs to kill cancer cells throughout the body. Nearly 70 percent of patients with hematologic tumors received chemotherapy, compared to about half of those with soft-tissue tumors. Radiation therapy was used less frequently for both groups, but it was notably more common in the soft-tissue group than in the hematologic group.

The researchers also examined how long patients lived after their diagnosis, though they were careful to note that their data could not prove that one treatment was better than another. They observed that patients with hematologic tumors who received chemotherapy tended to live longer than those who did not. However, the study authors explained that this difference might not be because the drugs worked perfectly, but rather because patients who were too sick to survive long enough to receive treatment were automatically placed in the "no treatment" group. Similarly, for soft-tissue tumors, those who received chemotherapy appeared to live longer initially, but the survival rates for both treated and untreated groups eventually converged after ten years, with very few patients remaining alive in either group. This suggests that while treatment might help in the short term, the long-term outlook for these cancers remains very difficult.

The study also tracked the number of new cases reported each year. From 2000 to 2021, the total number of recorded cases increased, rising from an average of about 25 cases per year in the early 2000s to nearly 47 cases per year in the most recent decade. This increase happened for both soft-tissue and hematologic tumors. The researchers noted that this rise does not necessarily mean that more people are developing these cancers. Instead, it likely reflects better detection methods, such as advanced imaging techniques like MRI and CT scans, which allow doctors to find these rare tumors more often than they could in the past. The proportion of hematologic tumors within the total group remained steady at roughly 30 percent throughout the entire period, indicating that the balance between these two types has not shifted.

Despite the clear patterns in demographics and treatment, the researchers emphasized several important limitations. The data came from a registry that records what happened, not why it happened. They did not have information on when exactly treatments started, which makes it difficult to know if a patient survived longer because of the treatment or because they were healthy enough to receive it. They also lacked details on the specific drugs used, the success of the surgeries, or whether the cancer had spread to other organs. Furthermore, the study relied on the codes used by hospitals to classify the tumors, which may not always be as precise as a specialized pathologist's review. Because of these factors, the findings describe what is recorded in the database rather than proving the effectiveness of any specific therapy.

Ultimately, this research serves as a crucial step in understanding primary malignant cardiac tumors by showing that they are not a single disease. The clear separation between soft-tissue and hematologic tumors, with their distinct age groups, specific cancer types, and different treatment approaches, argues against treating all heart cancers the same way. The findings suggest that future medical research and clinical care should focus on these specific subtypes. By recognizing that a soft-tissue tumor is a different challenge than a blood-based tumor, doctors can better tailor their strategies, even if the current data does not yet offer a definitive solution for survival. The study provides a solid foundation of facts, showing that while these cancers remain rare and deadly, they are becoming more visible and better understood through the lens of their specific biological origins.